{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-250676","form_type":"8-K","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2025-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.354655+00:00","generated_at":"2026-05-17T02:12:30.009654+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cabaletta Bio: all DM/ASyS myositis patients meet registrational endpoint; SSc and lupus data positive","bullets":["All 4 DM/ASyS patients with sufficient follow-up achieved immunomodulatory-free moderate or major TIS response at week 16.","Initiating DM/ASyS registrational cohort this quarter; plans 14 patients with 16-week primary endpoint of moderate or major TIS.","All 4 SSc patients with at least 3 months follow-up achieved rCRISS-25 response off all immunomodulators and steroids.","7 of 8 lupus patients with sufficient follow-up achieved DORIS remission or renal response; all 9 patients off immunomodulators.","Expanding RESET-SLE to include no preconditioning cohort; initial data expected 2026; 76 patients enrolled at 77 sites globally."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-250676","json":"https://secwatch.observer/filing/0001193125-25-250676.json","markdown":"https://secwatch.observer/filing/0001193125-25-250676.md","text":"https://secwatch.observer/filing/0001193125-25-250676.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000119312525250676/0001193125-25-250676-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000119312525250676/caba-20251027.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:12:30.009654+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}